Bioverse review

Bioverse previously advertised NAD⁺ from $259/month and described a vial with supplies, without establishing the shortest plan or full charge. Current public pages could not be reached, so those earlier offers and the conflicting ten- and eighteen-state lists remain unconfirmed. Obtain current eligibility, pharmacy, supply and billing terms before paying.

Earlier Bioverse pages described a longevity telehealth platform operated by Bioverse, Inc., with NAD⁺ and glutathione injections alongside a broader wellness and weight-loss menu. They displayed a LegitScript seal and attributed medical services to Outlast Health PA and affiliates. These are earlier seller disclosures, not current confirmation of operations, products, certification or patient-specific assignment. The public site’s present access failure does not establish that the business has closed.

Earlier pages described online provider review, messaging and shipping included, and terms attributed medical services to Outlast Health PA and affiliates. The NAD⁺ dispensing pharmacy was unconfirmed, and the homepage carried both ten- and eighteen-state lists. Current care arrangements and eligibility could not be reconfirmed. Request the actual prescriber, dispensing pharmacy and monitoring plan.

The earlier NAD⁺ page advertised from $259/month and separately described a 5 mL vial at 200 mg/mL with needles and syringes. Neither the quote nor that vial’s current availability is confirmed; the listing did not tie the vial to the quoted plan, supply duration or full upfront charge. Earlier terms allowed early renewal charges, required cancellation at least 48 hours before processing and ended medication cancellation when the provider ordered it, with final prescription sales and no partial-period refund. Those are historical terms; obtain the current fee schedule, renewal date and cancellation contract in writing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Earlier pages described NAD⁺ and glutathione injections as compounding-pharmacy preparations, not therapeutically equivalent to any approved drug; the current offer and dispensing pharmacy are unconfirmed — a real gap, because compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are. The brand-name GLP-1s in Bioverse’s earlier menu are FDA-approved, and the two tiers should not be conflated. On the evidence, the longevity line needs stating plainly. Injected NAD⁺ has no controlled human outcome trials supporting the energy, focus or longevity claims attached to it; the one human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly. The NAD⁺ evidence that exists belongs to the oral precursors NR and NMN, which reliably raise blood NAD⁺ in controlled studies — a raised biomarker, not a demonstrated clinical outcome. Injectable glutathione has essentially no controlled human outcome evidence for the wellness and skin claims made about it. Individual results vary.